Impact of venetoclax-based therapies on CLL-associated autoimmune cytopenias: A retrospective study conducted by ERIC.
Venetoclax-based therapy shows promise for managing autoimmune blood cell deficiencies that sometimes occur with chronic lymphocytic leukemia.
This PubMed-indexed study examined impact of venetoclax-based therapies on cll-associated autoimmune cytopenias: a retrospective study conducted by eric. Hemasphere 2026 Nov 6;10(11):e70522.
What the study was
- Study design
- Retrospective multicenter cohort study
- Population
- Human participants or human evidence described in the PubMed abstract
- Sample size
- 1720
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- HemaSphere
Why it surfaced
Retrospective multicenter cohort study with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.